entertainment -WSS

entertainment

author：comprehensive 2025-09-30 16:29:11 - browse：32479

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

A group of advisers to the Food and Drug Administration voted in favor of Alnylam Pharmaceuticals’ treatment for a debilitating heart disease Wednesday, but only after a day-long debate challenging whether the drug’s modest observed effects were actually meaningful for patients.

The group of independent experts voted 9-3 that the benefits of Alnylam’s drug, called patisiran, outweighed its risks for patients with ATTR-CM, a progressive disease that leads to fatal heart failure if left untreated. The FDA, which is not required to follow the advice of advisers, is expected to make a final decision on patisiran by Oct. 8.

“It’s like a light wind blowing in favor of patisiran over placebo,” said David Cella, a neurologist at the Northwestern University Feinberg School of Medicine who voted in favor of patisiran. David Moliterno, a cardiologist at the University of Kentucky, added that “the good news in this story is that while there may be a small benefit, it doesn’t look like there’s a signal for harm.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Intercept Pharmaceuticals sells itself for less than $1 billion

explore

WSS

What's changing in Medicare's open enrollment this year?

Paxlovid should be available without a positive Covid test

Nick Jonas talks about managing diabetes along with his career

After a drawn out lobbying fight, ARPA

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Medicare to cover more brain scans related to Alzheimer’s drugs

leisure time

entertainment

focus

Bright Health sells Medicare Advantage business to Molina

How one patient went off dialysis — and others can too

State Dept. review finds Biden bears some blame for Afghanistan failures

Akero's treatment for NASH falls short in cirrhosis study

Supreme Court strikes down use of affirmative action

Health tech startups drop sharply from 2021 highs

Wildfire smoke exposes gaps in outdoor worker protections

There’s no way to know how good AI health technologies are

Virginia high school admissions case could be legal follow

Peter Marks talks Operation Warp Speed for Rare Diseases

explore

After a drawn out lobbying fight, ARPA

Massive project maps cells in human brain in unprecedented detail

Ionis has late

Ionis has late

How should state employee insurance handle Wegovy?

Covid vaccines: Private market messier than government rollout

entertainment

hotspot

explore

hotspot